Valuation: CorMedix Inc.

Market Cap 557M 483M 452M 412M 775M 53.13B 787M 5.32B 2.08B 26.6B 2.09B 2.05B 88.7B P/E 2026 *
14.1x
P/E 2027 * 80.7x
Enterprise Value 557M 483M 452M 412M 775M 53.13B 787M 5.32B 2.08B 26.6B 2.09B 2.05B 88.7B EV / Sales 2026 *
1.66x
EV / Sales 2027 * 1.95x
Free-Float
92.47%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-09
Director of Finance/CFO 54 2025-08-28
Compliance Officer 66 2023-12-11
Director TitleAgeSince
Director/Board Member 67 2015-08-05
Chairman 81 2017-08-02
Director/Board Member 70 2011-08-15
Change 5-day change 1-year change 3-year change Capi.($)
-8.19%-1.19% - - 573M
+1.92%+3.58%+65.53%+23.72% 322B
0.00%-3.45%+26.07%-14.27% 70.24B
-0.81%+21.77%+58.95%+132.66% 11.65B
+0.21%+3.24%-1.35%-2.81% 8.42B
-2.54%+7.56%-10.73%-6.86% 5.02B
-2.92%+10.65%-25.14%+15.26% 4.52B
-0.76%+13.44%+2.89%+48.08% 4.25B
+2.11%+2.05%+16.08%+50.11% 2.72B
-2.00%-0.14%-1.79%-1.14% 2.28B
Average -1.30%+6.44%+14.50%+27.20% 47.87B
Weighted average by Cap. +1.34%+3.04%+54.49%+19.78%

Financials

2026 *2027 *
Net sales 335M 290M 272M 248M 466M 31.91B 473M 3.19B 1.25B 15.98B 1.26B 1.23B 53.28B 285M 247M 232M 211M 397M 27.2B 403M 2.72B 1.06B 13.62B 1.07B 1.05B 45.42B
Net income 47.14M 40.84M 38.27M 34.91M 65.62M 4.5B 66.63M 450M 176M 2.25B 177M 173M 7.51B 8.61M 7.46M 6.99M 6.38M 11.99M 821M 12.17M 82.2M 32.13M 411M 32.33M 31.62M 1.37B
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-